Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “KMT2A”

57 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 57 results

Early research (Phase 1)Not Yet RecruitingNCT07283640
What this trial is testing

A Phase IB Trial of Subcutaneous Blinatumomab in Combination With Revumenib for Patients With KMT2A-rearranged Acute Lymphoblastic Leukemia

Who this might be right for
BlinatumomabRevumenibLymphoblastic Leukemia+1 more
M.D. Anderson Cancer Center 20
Large-scale testing (Phase 3)Looking for participantsNCT07223814
What this trial is testing

Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)

Who this might be right for
Acute Myeloid Leukemia
Stichting Hemato-Oncologie voor Volwassenen Nederland 875
Testing effectiveness (Phase 2)Looking for participantsNCT07356154
What this trial is testing

Revumenib and Mezigdomide in People With Leukemia

Who this might be right for
LeukemiaAcute LeukemiaRelapse Leukemia+5 more
Memorial Sloan Kettering Cancer Center 52
Early research (Phase 1)Active Not RecruitingNCT05453903
What this trial is testing

Bleximenib in Combination With Acute Myeloid Leukemia (AML) Directed Therapies

Who this might be right for
Leukemia, Myeloid, Acute
Janssen Research & Development, LLC 196
Testing effectiveness (Phase 2)Looking for participantsNCT04276870
What this trial is testing

Orphan Indications for CD19 Redirected Autologous T Cells

Who this might be right for
Pediatric and Young Adult Patientswith Hypodiploid or t(17;19) B-ALLInfants With Very High Risk KMT2A B-ALLPatients With Central Nervous System Relapse Who Did Not Receive Cranial Radiation or Bone Marrow Transplantation
Stephan Grupp MD PhD 133
Early research (Phase 1)Not Yet RecruitingNCT07355335
What this trial is testing

Ziftomenib + Mezigdomide in Adolesc. and Adults w/ R/R AML

Who this might be right for
KMT2A-rearrangedNPM1-mutant Refractory or Relapsed AML
Massachusetts General Hospital 24
Testing effectiveness (Phase 2)Looking for participantsNCT04988555
What this trial is testing

Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

Who this might be right for
Leukemia, Myeloid, AcuteLeukemia, Lymphocytic, AcuteMultiple Myeloma+1 more
Sumitomo Pharma America, Inc. 606
Early research (Phase 1)Looking for participantsNCT05735184
What this trial is testing

Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

Who this might be right for
Acute Myeloid LeukemiaMixed Lineage Leukemia Gene MutationRefractory AML+7 more
Kura Oncology, Inc. 420
Early research (Phase 1)Active Not RecruitingNCT03513484
What this trial is testing

Nintedanib and Azacitidine in Treating Participants With HOX Gene Overexpression Relapsed or Refractory Acute Myeloid Leukemia

Who this might be right for
Acute Myeloid Leukemia With t(9;11)(p22.3;q23.3); MLLT3-KMT2AFibroblast Growth Factor Basic Form MeasurementFLT3 Internal Tandem Duplication+2 more
Northwestern University 44
Early research (Phase 1)Looking for participantsNCT03826992
What this trial is testing

Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia

Who this might be right for
Leukemia
Children's Hospital Medical Center, Cincinnati 21
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07722312
What this trial is testing

S243249 Monotherapy in Patients With Relapsed or Refractory Acute Leukemia With a KMT2A or NUP98 Translocation or Relapsed or Refractory AML With NPM1c Mutation

Who this might be right for
Relapsed or Refractory Acute LeukemiaRelapsed or Refractory Acute Myeloid Leukemia
Servier 80
Early research (Phase 1)Study completedNCT01139970
What this trial is testing

Veliparib and Temozolomide in Treating Patients With Acute Leukemia

Who this might be right for
Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaAcute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome+13 more
National Cancer Institute (NCI) 66
Early research (Phase 1)Ended earlyNCT03579888
What this trial is testing

CD19-Specific T Cells Post AlloSCT

Who this might be right for
B Acute Lymphoblastic Leukemia With t(v;11q23.3); KMT2A RearrangedRecurrent B Acute Lymphoblastic LeukemiaRecurrent Chronic Lymphocytic Leukemia+14 more
M.D. Anderson Cancer Center 4
Testing effectiveness (Phase 2)Study completedNCT00416598
What this trial is testing

Decitabine as Maintenance Therapy After Standard Therapy in Treating Patients With Previously Untreated Acute Myeloid Leukemia

Who this might be right for
Acute Myeloid LeukemiaAcute Myeloid Leukemia With Myelodysplasia-Related ChangesAdult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11+4 more
National Cancer Institute (NCI) 546
Large-scale testing (Phase 3)Looking for participantsNCT07007312
What this trial is testing

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

Who this might be right for
Acute Myeloid Leukemia (AML)
Kura Oncology, Inc. 1,300
Early research (Phase 1)Active Not RecruitingNCT06226571
What this trial is testing

Revumenib in Combination With Intensive Chemotherapy in Participants With Acute Myeloid Leukemias

Who this might be right for
Acute Myeloid Leukemias
Syndax Pharmaceuticals 96
Large-scale testing (Phase 3)Study completedNCT01307579
What this trial is testing

Caspofungin Versus Fluconazole in Preventing Invasive Fungal Infections (IFI) in Patients Undergoing Chemotherapy for Acute Myeloid Leukemia

Who this might be right for
Acute Myeloid LeukemiaAdult Acute Monoblastic LeukemiaAdult Acute Monocytic Leukemia+25 more
Children's Oncology Group 517
Testing effectiveness (Phase 2)Ended earlyNCT03724084
What this trial is testing

Pinometostat With Standard Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and MLL Gene Rearrangement

Who this might be right for
Acute Myeloid Leukemia
National Cancer Institute (NCI) 6
Early research (Phase 1)Looking for participantsNCT06222580
What this trial is testing

SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation

Who this might be right for
Acute Myeloid Leukemia With FLT3/ITD MutationAcute Myeloid Leukemia With KMT2A RearrangementAcute Myeloid Leukemia With NPM1 Mutation+2 more
Uma Borate 30
Early research (Phase 1)Study completedNCT00588991
What this trial is testing

Veliparib and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leukemia, High-Risk Myelodysplasia, or Aggressive Myeloproliferative Disorders

Who this might be right for
Adult Acute Megakaryoblastic LeukemiaAdult Acute Monoblastic LeukemiaAdult Acute Monocytic Leukemia+20 more
National Cancer Institute (NCI) 12
Next Page